Becton, Dickinson and Company $BDX Position Trimmed by Laurel Wealth Advisors LLC

Laurel Wealth Advisors LLC reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 99.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,036 shares of the medical instruments supplier’s stock after selling 1,570,350 shares during the quarter. Laurel Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,691,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. SOA Wealth Advisors LLC. boosted its holdings in shares of Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 95 shares during the period. Activest Wealth Management lifted its position in Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 97 shares during the last quarter. Bell Investment Advisors Inc lifted its position in Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the last quarter. Cornerstone Planning Group LLC boosted its stake in Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 139 shares during the period. Finally, Accredited Wealth Management LLC grew its position in Becton, Dickinson and Company by 77.8% in the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 70 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,416 shares of company stock worth $674,693 over the last quarter. Insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada set a $172.00 price objective on Becton, Dickinson and Company in a research report on Tuesday, February 10th. TD Cowen lifted their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. reduced their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Wells Fargo & Company lowered their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 10th. Finally, Bank of America lifted their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Stock Down 0.4%

Shares of BDX stock opened at $176.04 on Monday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market cap of $50.12 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 12.79 and a beta of 0.24. The business’s fifty day moving average is $195.68 and its 200-day moving average is $192.03. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. The business had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company’s revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s payout ratio is currently 68.52%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.